Connect with us

Healthcare

Iol Chemicals and Pharmaceuticals Limited (iolcp) Q4 & FY26 Results: Highest-ever Quarterly Revenue with 15%+ Ebitda Margin

IOL Chemicals and Pharmaceuticals Limited (IOLCP) reports Q4 & FY26 results with highest-ever quarterly revenue and significant EBITDA margin growth.

priyanka verma tradealone

Published

on

Iol Chemicals and Pharmaceuticals Limited IOLCP Q4 FY26 Results

IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced its financial results for the quarter and full year ended 31st March 2026. The company achieved its highest-ever quarterly revenue, driven by strong momentum across both Pharmaceuticals and Chemicals businesses. EBITDA and PAT recorded significant growth, while margins expanded meaningfully on a year-on-year basis.

Pharmaceuticals Segment Highlights

The Pharmaceuticals business demonstrated strong growth, led by increasing contributions from the non-Ibuprofen portfolio. Key products such as Paracetamol, Metformin, and other APIs witnessed healthy traction, reflecting the company’s ongoing diversification strategy. The improving product mix, combined with IOL’s position as one of the lowest-cost producers in key molecules, supported stronger profitability and margin expansion in the Pharma segment.

Chemicals Segment Performance

The Chemicals business delivered strong performance during the quarter, with segment EBIT nearly doubling year-on-year, supported by improved realizations, stable demand conditions, and operational efficiencies. Capacity enhancements in Ethyl Acetate, Acetic Anhydride along with the addition of Triacetin capacity will further strengthen the company’s manufacturing capabilities, support backward integration, and drive future growth.

Looking Ahead

IOL remains focused on driving disciplined expansion, deepening its presence in regulated as well as non-regulated markets, and enhancing operational efficiencies, supported by a diversified product portfolio and a strong execution track record.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

IOLCP
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
34
Fundamental
78
Technical
56
Overall

1W -6.02%
1M -2.03%
3M +18.27%
P/E: 27.6 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

IOL gains 61.0% over three months and trades near its 52-week highs. Thin margins at 5.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at -1.6% CAGR. That signals structural headwinds, not a short-term blip. RSI hits 77, a level that signals the stock runs hot. Notably, buyers drove volume on 20 recent sessions — though at these levels, some profit-taking is normal. The stock rises 61.0% in three months. Yet revenue grows at only -1.6% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of IOL Chemicals and Pharmaceuticals Limited.

GLENMARK

Glenmark Pharmaceuticals Limited (glenmark) Announces IND Submission for ISB 2301

Glenmark Pharmaceuticals Limited (GLENMARK) announces IND submission for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.

Pranab Tyagi at TradeAlone

Published

on

Glenmark Pharmaceuticals Limited Glenmark IND Submission

Glenmark Pharmaceuticals Limited (GLENMARK) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301. The focus keyword, Glenmark Pharmaceuticals Limited GLENMARK IND Submission, highlights this significant milestone in the company’s oncology pipeline. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and natural killer (NK) cells.

Advancement in Multispecific Oncology Pipeline

The IND submission marks an important step in advancing Ichnos Glenmark Innovation’s (IGI) multispecific oncology pipeline into clinical development. ISB 2301, engineered using IGI’s proprietary BEAT® Multispecific Platform, combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. This pentaspecific molecule is designed to address biological heterogeneity and immune-suppressive features of solid tumors.

Planned Phase 1 Clinical Trial

IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumors in 2027. Preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, showing favorable pharmacokinetic and tolerability profiles in non-human primates. The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of ISB 2301 in patients with advanced solid tumors.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GLENMARK
Healthcare › Drug Manufacturers - Specialty & Generic
BREAKOUT
78
Fundamental
94
Technical
86
Overall

1W -2.07%
1M +17.47%
3M +12.31%
P/E: 50.9 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Glenmark rises 12.3% over three months, with buying pressure holding steady. The PEG of 0.77 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 9.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.77 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.

Continue Reading

Drug Manufacturers - General

Sai Parenterals Limited (saiparent) Acquires Majority Stake in Bion Therapeutics’ Prescription Business

Sai Parenterals Limited (SAIPARENT) announces acquisition of Bion Therapeutics’ prescription business, adding 16 brands and enhancing market presence.

Pranab Tyagi at TradeAlone

Published

on

Sai Parenterals Limited Saiparent November 2026 Acquisition

Sai Parenterals Limited (NSE: SAIPARENT) has announced a strategic move to acquire a majority stake in Bion Therapeutics India Private Limited (Bion), a Hyderabad-based branded formulations prescription business company. This acquisition, executed through its wholly owned subsidiary SP Analytics Private Limited, is expected to be finalized before the end of this month. The transaction will be an all-cash deal, significantly strengthening Sai Parenterals’ presence in India’s prescription market.

Strategic Benefits

The acquisition of Bion Therapeutics will add 16 established brands and around 250 field staff to Sai Parenterals, enhancing its competitive position in the domestic pharmaceutical landscape. Bion’s extensive infrastructure provides immediate access to a broader market, integrating with Sai Parenterals’ manufacturing capabilities to ensure assured supply, consistent quality, and improved margins.

Operational Integration

Bion’s portfolio, currently manufactured by third parties, will progressively transfer to Sai Parenterals’ accredited facilities, which hold TGA-Australia and WHO-GMP accreditations. This move will allow Bion’s brands to leverage Sai Parenterals’ development pipeline and Noumed’s dossier library, offering a wider portfolio to its existing doctor coverage. The critical-care injectable facility, SAICRITI, due for completion in August 2027, will provide a route into hospital and critical-care segments for Bion’s injectable brands.

Forward-Looking Vision

Commenting on the agreement, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, emphasized the strategic importance of this acquisition in converting development capability into branded revenue. The value flows in both directions, with Bion’s portfolio transferring to Sai Parenterals’ facilities and Sai Parenterals’ development pipeline broadening Bion’s market offerings. Further particulars of the transaction will be disclosed at the appropriate stage.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SAIPARENT
Healthcare › Drug Manufacturers - General
APPROACHING SUPPORT
72
Fundamental
62
Technical
68
Overall

1W -1.89%
1M +1.9%
3M -10.04%
P/E: 88 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Sai falls 8.2% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 57.9% and profits at 48.3% CAGR. Both numbers are exceptional. The stock gains 3.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 57.9% and profits at 48.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 8.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.

Continue Reading

Healthcare

Orchid Pharma Limited Unveils ‘soil to Vialfrom’ Initiative

Orchid Pharma Limited (ORCHPHARMA) reports strong Q2 FY27 results with a 148% surge in EBITDA, highlighting the success of its ‘Soil to VialFROM’ initiative.

seema chauhan author

Published

on

Orchid Pharma Limited Orchpharma Q2 FY27 Results

Orchid Pharma Limited (ORCHPHARMA) has announced impressive financial results for Q2 FY27, marking a significant milestone with its ‘Soil to VialFROM’ initiative. The company’s standalone EBITDA surged by 148% compared to the same period last year, reflecting robust growth and operational efficiency. This remarkable performance underscores the successful integration of Orchid Pharma Limited and Dhanuka Laboratories Ltd., which was sanctioned under the NCLT scheme effective from July 10, 2026.

Financial Performance Highlights

The financial performance for Q2 FY27 showcases a 14% increase in revenue from operations, reaching Rs 341 crore. The gross margin improved to 15%, up from 7% in Q2 FY26. Notably, the EBITDA margin expanded to 12%, highlighting the company’s strong operational leverage. The profit after tax (PAT) for the quarter stood at Rs 37 crore, a substantial improvement from Rs 7 crore in Q2 FY26.

Strategic Growth Initiatives

The ‘Soil to VialFROM’ initiative, which spans from fermentation and biotransformation to finished dosage, is central to Orchid Pharma’s growth strategy. This comprehensive approach not only enhances the company’s capabilities in API manufacturing but also positions it as a leader in the global anti-infectives market. The initiative is expected to drive sustained long-term growth, leveraging Orchid Pharma’s 30 years of expertise in cephalosporin development.

As Orchid Pharma Limited continues to expand its footprint in regulated markets, the company remains committed to innovation and disciplined expansion, aiming to address the growing demand for novel antibiotics and advanced therapeutic solutions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Orchid Pharma Limited

Orchid Pharma Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ORCHPHARMA
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
56
Fundamental
70
Technical
64
Overall

1W +5.3%
1M +2.15%
3M -6.76%
P/E: 578.2 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Orchid holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 1.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -7.4% in three months on 22.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Orchid Pharma Limited.

Continue Reading

Trending

Exit mobile version